-
Musk's Grok created three million sexualized images, research says
-
Gazans pay homage to Palestinian journalists killed by Israel
-
With 'Board of Peace,' Trump tries hand at institution-making, to wide doubt
-
At Davos, Zelensky blasts EU, says US 'security guarantees' ready
-
French navy boards tanker 'from Russia' in Mediterranean
-
Trump takes Davos on wild ride
-
Venezuela moves to liberalize oil sector, in boost for Trump
-
Venezuela looks to petrodollars to bring down prices
-
Europe relieved but 'vigilant' after Trump Greenland climbdown
-
Freezing Kyiv residents seek warmth in trains and tents
-
Musk makes Davos debut with promise of robots for all
-
Track star Sydney McLaughlin-Levrone announces pregnancy
-
NYC sues to block Dr. Phil-fronted police documentary
-
Basking in Oscar nod, Russian videographer ready for Hollywood
-
WTO chief slams rise of trade protectionism
-
Sri Lanka seal 19-run win over England in opening ODI
-
Germany expels Russian alleged spy handler, Moscow vows response
-
Casemiro to leave Man Utd at end of season
-
Frank says troubled Spurs 'going in right direction'
-
Springboks to meet All Blacks in USA for first time
-
Men's fashion turns to embroidery as guys want 'something different’
-
In fiery Davos speech, Zelensky blasts EU, says US 'security guarantees' ready
-
Macron squares up to Trump in rebel shades at macho Davos gathering
-
Storms, heavy rain kill 14 across Afghanistan
-
Injuries force two changes in South Africa T20 World Cup squad
-
In Greenland, locals fed up with deals done over their heads
-
Ex-marathon record holder Kosgei trades Kenya for Turkey at Olympics
-
Ariana snubbed and Chalamet supreme? Five Oscars takeaways
-
Germany summons Russian envoy, expels alleged spy handler
-
Iran warns 'finger on trigger' as Trump says it wants talks
-
Wary Europeans huddle after Trump Greenland climbdown
-
Real Madrid stadium owners to face trial over concert noise
-
'Sinners' breaks all-time Oscars record with 16 nominations
-
South Africa's Kruger park suffers 'devastating' damage from floods
-
Molinari leads Dubai Desert Classic as McIlroy struggles
-
Ligue 1 leaders Lens still waiting for PSG title charge
-
US touts 'New Gaza' filled with luxury real estate
-
Athens hit with several months of rain in one day: expert
-
Trump unveils Board of Peace, 'New Gaza' plans at Davos
-
Ubisoft shares plunge after big-bang restructuring announced
-
Mendis' unbeaten 93 anchors Sri Lanka to 271-6 against England
-
Reeling Napoli face Juve after 'unacceptable' Champions League showing
-
Actor Liz Hurley in tears as accuses UK tabloid of 'monstrous' conduct
-
What we know about Trump's Greenland 'framework' deal
-
Osaka 'confused' as testy exchange sours Australian Open win
-
Trump launches 'Board of Peace' at Davos
-
Stocks rally as Trump drops Greenland tariff threats
-
Mercedes unveil 2026 F1 car for new 2026 rules
-
Djokovic, Sinner plough on in Melbourne, Wawrinka makes history
-
Kitzbuehel's Hahnenkamm, the terrifying Super Bowl of skiing
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
G.Schulte--BTB